Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - response to scrutiny letter
|
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): Roche - response to scrutiny letter
16 May 2011 (66.09 Kb 19 sec) |
This page was last updated: 13 May 2011